CGC Stock Analysis: Buy, Sell, or Hold?
CGC - Canopy Growth Corporation Common Shares
$0.95
-0.01 (-1.14%)
▼
5d:
-3.73%
30d:
-11.57%
90d:
-2.1%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jun 15, 2026
0d
Get Alerted When CGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CGC shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CGC shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CGC is currently trading at $0.95, which is considered oversold relative to its 30-day fair value range of $0.98 to $1.07. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.7) compared to its historical average (13.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CGC is showing sideways momentum. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $1.78 (+87.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGC is showing sideways momentum. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $1.78 (+87.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.98 -
$1.07
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 87.6% below Wall St target ($1.78)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.98 -
$1.07
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.94
Resistance Level
$1.09
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.70
Wall Street Target
$1.78
(+87.6%)
Revenue Growth (YoY)
9.6%
Profit Margin
-92.4%
PE vs Historical
-3.7 vs 13.0
CHEAP
Share & Embed Analysis
Last updated: June 24, 2026 3:37 AM ET
Data refreshes hourly during market hours. Next update: 4:37 AM
Data refreshes hourly during market hours. Next update: 4:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Joseph Bayern
SELL
2658 shares
2026-03-31
M Shan Atkins
SELL
2074 shares
2026-03-31
Theresa Yanofsky
SELL
10373 shares
2026-03-31
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
Advanced CGC Option Strategies
Professional options setups generated by AI based on today's CGC price and gamma walls.
